The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst); Merck (Inst); Pfizer (Inst)
Safety and clinical activity of first-line durvalumab in advanced NSCLC: Updated results from a Phase 1/2 study.
 
Scott Joseph Antonia
Stock and Other Ownership Interests - Cellular Biomedicine Group
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck
 
Julie R. Brahmer
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Janssen Oncology; Lilly; Merck; Syndax
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Five Prime Therapeutics (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck
Other Relationship - Bristol-Myers Squibb; merck
 
Ani Sarkis Balmanoukian
Speakers' Bureau - Bristol-Myers Squibb; Genentech; Merck
Research Funding - Genentech; Incyte; MedImmune; Merck; Merck Serono
 
Dong-Wan Kim
No Relationships to Disclose
 
Sang-We Kim
No Relationships to Disclose
 
Myung-Ju Ahn
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck; MSD; Ono Pharmaceutical; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck; MSD; Ono Pharmaceutical; Roche
 
Rahima Jamal
No Relationships to Disclose
 
Dirk Jaeger
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Roche
 
Patrick Alexander Ott
Consulting or Advisory Role - Alexion Pharmaceuticals; Amgen; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Genentech; Neon Therapeutics
Research Funding - ARMO BioSciences (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Merck (Inst)
 
Paolo Antonio Ascierto
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
 
Vanesa Gregorc
No Relationships to Disclose
 
Jonathan Wade Goldman
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Genentech/Roche; Lilly; Trovagene; Vortex Biosciences
Research Funding - Abbvie; Array BioPharma; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca/MedImmune; Bristol-Myers Squibb; Celgene; Clovis Oncology; Corvus Pharmaceuticals; Genentech/Roche; Lilly; Threshold Pharmaceuticals
 
Collin M. Blakely
Research Funding - Clovis Oncology (Inst); Ignyta (Inst); MedImmune (Inst); Mirati Therapeutics (Inst)
 
Xiaoping Jin
Employment - MedImmune
Stock and Other Ownership Interests - AstraZeneca
 
Joyce Antal
Employment - MedImmune
Stock and Other Ownership Interests - AstraZeneca
 
Ashok Kumar Gupta
Employment - MedImmune
Stock and Other Ownership Interests - AstraZeneca; Bristol-Myers Squibb
 
Neil Howard Segal
Honoraria - MedImmune
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Calithera Biosciences; Imugene; Kyocera; Macrogenics; Pfizer; Roche/Genentech
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Pfizer; Roche/Genentech